Our antibodies are used worldwide

We are the original manufacturer and provider of over 21,000 validated primary antibodies extensively covering the human proteome

Our antibodies to understand Ketogenic diet’s effect on brain cells

September 2022 (Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany)

Neuroscience: Ketogenic diet uncovers differential metabolic plasticity of brain cells.

The ketogenic diet is a low-carbohydrate, high-fat regime in which ketone bodies are utilized instead of glucose as an energy source.

Anti-DHX9 and Anti-SCO1 antibodies in research on the impact of histone density on cancer biology

September 2022 (The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy)

The histone landscape in humans is complex: while there is only one histone H4 protein, diverse variants exist for H2A, H2B, and H3.

Anti-ACOX2 TripleA Polyclonal antibody in lung cancer research

September 2022 (Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA)

Our anti-DLX5 Triple A polyclonal antibody in reproductive organs development research

August 2022 (University of Texas MD Anderson Cancer Center, Houston, United States)

The reproductive tract organs of mammals are derived from two pairs of epithelial tubes surrounded by mesenchyme called the Wolffian ducts (progenitor male reproductive tract) and Müllerian ducts (progenitor female reproductive tract).

Anti-TOMM20 polyclonal helps to reveal mitochondria's contribution to inflammatory responses

August 2022 (School of Kinesiology, Shanghai University of Sport, Shanghai, 200438, China)

Mitochondria's contribution to inflammatory responses.

Renal cell carcinoma research and anti-DSP polyclonal antibody

August 2022 (Department of Clinical Medicine, University of Bergen, 5021, Bergen, Norway)

Our anti-S100b monoclonal in wound healing research

August 2022 (Shanghai Jiao Tong University School of Medicine, China)

Schwann cells facilitate wound healing by releasing TGF-β3.

Squamous cell carcinomas and our anti-TMTC3 antibody

July 2022 (Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China)

Squamous cell carcinomas show a specific expression pattern of TMTC3. Moreover, high expressions of TMTC3 are associated with poor survival in esophageal squamous cell carcinomas patients.

Anti-MUC5B rabbit polyclonal in SARS-CoV-2 research

July 2022 (Department of Biomedical Sciences, University of North Dakota School of Medicine & Health Sciences, Grand Forks, North Dakota, USA)

SARS-CoV-2 preferentially infects goblet cells in the bronchial airway epithelium. Goblet cells are a specialized type of epithelial cell that secrete mucins (MUCs), significant mucus components.

Five of our antibodies in cortical neural stem cell research

July 2022 (Max Planck Institute for Molecular Genetics, Berlin, Germany)

The anti-TINAGL1 polyclonal antibody for breast cancer research

June 2022 (Nagoya City University Graduate School of Medical Sciences, Japan)

TINAGL1: a promising candidate biomarker and therapeutic target in breast cancer patients.

Our anti-CCL28 Triple A Polyclonal antibody in Lung disease research

June 2022 (Sanger Institute, Hinxton, CambridgeshireUnited Kingdom)

Urothelial carcinomas research and our anti-PYGB polyclonal antibody

May 2022 (Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea)

Our Anti-ANLN polyclonal antibodies in research on various types of cancer

May 2022 (Department of General Surgery, Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, Anhui, China)

Using our Anti-ANLN polyclonal antibodies (HPA005680, HPA050556) this comprehensive analysis (Yanlong Shi, et al. 2022) reveals the carcinogenic and immunological roles of ANLN in human cancers. 

Six antibodies from Atlas Antibodies used in multiplexing

May 2022 (Technology Innovation Lab, New York Genome Center, USA)

"An open source toolkit for repurposing Illumina sequencing systems as versatile fluidics and imaging platforms".

Fluorescence microscopy is a crucial method in the life sciences. It requires automated execution to generate robust and reproducible data.

Accessibility to software, hardware, and protocol open platforms is therefore necessary to facilitate analysis and programmable applications without specialized engineering or software development expertise.

Anti-CDK16 TripleA Polyclonal antibody in breast cancer research

May 2022 (Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China)

Anti-SGPL1 antibody used in mitochondrial dysfunction research

April 2022 (German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany)

Mitochondrial energy production is finely tuned to interpret cellular needs accurately.

Our polyclonal anti-RNF113A antibody in neural stem cells research

April 2022 (Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece)

RNF113A (Ring Finger Protein 113A) regulates survival and differentiation properties of neural stem cells.

Anti-SERPINA3 and anti-LGALS3BP antibodies in skin cancer research

April 2022 (Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia)

Malignant melanoma is the most severe type of skin cancer with the highest mortality rate.

Our rabbit anti-human LRG1 antibody used in blood vascular endothelial cells research

April 2022 (Institute of Pharmaceutical Sciences, Zurich, Switzerland)

Anti-EMSY polyclonal antibody in lung cancer research

March 2022 (Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, USA)

Lung cancer: deregulation of the ubiquitin-proteasome system promotes suppression of innate immunity, which fosters lung cancer immune evasion.

Using anti-PCYT2 polyclonal antibody in muscle health and muscle aging research


March, 2022 (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Austria)

Muscle degeneration (or muscle atrophy) is the wasting or thinning of muscle mass that leads to frailty and dependency in inherited diseases and aging, affecting hundreds of millions of people.

Anti-ARID1A polyclonal antibody in the study ”Relevance of ARID1A Mutations in Endometrial Carcinomas”

March, 2022 (Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy)

Using Atlas Antibodies rabbit anti-XK (HPA019036) polyclonal antibody for McLeod Syndrome and Chorea-Acanthocytosis diseases research


February, 2022 (Laboratory of Biochemistry and Immunology, Osaka University, Japan)

Three antibodies from Atlas Antibodies in Immuno Oncology - Hodgkin lymphoma research


February, 2022 (Department of Pathology and Medical Biology, University Medical Center Groningen, Netherlands)

Using anti-PPAT polyclonal antibody (HPA036091) in liver cancer research


January, 2022 (State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China)

Anti-CYBRD1 (HPA014757) antibody for Glioma research - increased expression of CYBRD1

November, 2021 (Department of Clinical Medicine, College of Medicine, Hunan University of Chinese Medicine, China)

Four Atlas Antibodies TripleA Polyclonals used in the study about IDH mutation


November, 2021 (Key Laboratory of Ministry of Education for Medicinal Plant Resource and Natural Pharmaceutical Chemistry, China)

Anti-PKM and Anti-GSTP1 rabbit polyclonals used in „Novel Diagnostic Protein Biomarkers in Colorectal Cancer“


September, 2021 (Department of Clinical Medicine - Department of Haematology, Aarhus, Denmark)

Novel putative protein biomarkers for colorectal cancer (CRC) identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with future  diagnostic potential.

Rabbit polyclonal anti-ADPRHL2/ARH3 used to gain insights into chromatin regulation and human disease


September, 2021 (University of Copenhagen, Denmark)

ADP-ribosylation is a reversible post-translational protein modification that regulates numerous processes, including DNA damage repair and chromatin remodeling.

Three antibodies anti-RBM3, anti-PDS5A and anti-PRR11 in pancreatic cancer research


August, 2021 (Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, Sweden)

Treatment options for patients with pancreatic cancer are limited, and chemotherapy remains the standard of care, leading to only modest survival benefits.

Anti-HRC antibody in study which defines HRC as a novel candidate oncogene involved in HCC metastasis


August, 2021 (Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)

Rabbit anti-human GOLGB1 polyclonal antibody in Centriole and Golgi microtubule nucleation research


July, 2021 (Molecular and Cellular Pharmacology Graduate Training Program, University of Wisconsin-Madison, USA)

Anti-human STK4 antibody in study to determine the most suitable therapy for the STK4-deficiency-related disease


June, 2021 (Department of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey)

Polyclonal antibodies against APOH and MGAM in Behçet’s disease (BD) and Crohn’s disease (CD) research


June, 2021 (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea)

Anti-Nanog (AMAb91393) monoclonal antibody in ovarian cancer study


May, 2021 (Division of Oncology, Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Sweden)

Anti-LRBA polyclonal antibody in a study ”Regulation of CTLA-4 recycling by LRBA and Rab11”


May, 2021 (Institute of Immunity and Transplantation, University College London, United Kingdom)

Cytotoxic T-lymphocyte-associated protein 4, also known as CTLA-4 or CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses.

Study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC using our anti-RAI2 polyclonal antibody

 

April, 2021 (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan)

Anti-HMCES polyclonal antibody in study which suggests that HMCES is an attractive target for selective treatment of A3A-expressing lung adenocarcinoma

 

April, 2021 (Institute for Research in Biomedicine, Barcelona, Spain)

The capacity to repair damaged DNA may modulate individual susceptibility to develop lung cancer.

Antibody Anti-SCGB2A1 used to explore the human lacrimal gland using organoids and single-cell sequencing

 

April, 2021 (Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, University Medical Center Utrecht, Netherlands)

Treatment options for patients with lacrimal gland disorders are limited partly due to a lack of biological understanding.

Our two polyclonal antibodies used to identify alternate receptors for SARS-CoV-2 that might facilitate initial host cell infection


April, 2021 (Department of Biology, University of Waterloo, Ontario, Canada)

Anti-Golga3 antibody in the study ”Novel players and large-scale protein dynamics of BCR activation revealed by APEX2 proximity labelling of lipid rafts”

 

March, 2021 (Institute of Biomedicine and MediCity Research Laboratories, University of Turku, Finland)

“Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma” study used Anti-RRM2 polyclonal antibody


March, 2021 (Hopp Children’s Cancer Center Heidelberg, Germany)

Study reporting increased SLC16A1 mRNA expression level in high-grade gliomas used our anti-SLC16A1 polyclonal antibody

 

March, 2021 (Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan)

Anti-TBX5 antibody and single-cell transcriptomic analysis uncover a novel relationship between specified cardiac progenitor cells and SHF progenitors

 

February, 2021 (Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, USA)